Stevens Institute of Technology Opens Biotechnology and Drug–Discovery Laboratory - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Stevens Institute of Technology Opens Biotechnology and Drug–Discovery Laboratory



The Center for Healthcare Innovation at Stevens Institute of Technology will open its Biotechnology and Drug-Discovery Laboratory in January 2014 as a new biotechnology and drug discovery enterprise that will partner with other Stevens faculty, students, and external academic and industry collaborators. Established in part with a donation of equipment and supplies from Hoffmann-La Roche and support from the New Jersey Department of Labor, seven former Roche personnel recently joined Stevens as faculty and researchers in this new initiative. Laboratory staff also includes three new professors with R&D experience in pharmaceutical and biotechnology corporate laboratories. The laboratory will serve as a center for research in the areas of preclinical gene cloning and purification of therapeutic proteins, assay development, and robotic drug screening.

Source: Stevens Institute of Technology

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
32%
Breakthrough designations
11%
Protecting the supply chain
37%
Expedited reviews of drug submissions
11%
More stakeholder involvement
11%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests

Click here